Category Archives: GLP-1RA

Welldoc Supports Launch of New Lilly Health App; NodThera Initiates Ph2 Study of NT-0796; Virta Claims Cost Savings for Obesity Programs

Three cardiometabolic-related news items have been observed: Welldoc announced it will power Lilly’s new app for obesity (view press release); NodThera initiated its Ph2 RESOLVE-1 study for NT-0796 in obesity (view press release); and Virta Health announced cost savings for health plans and employers utilizing its cardiometabolic programs (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register

Already a member? Log in here

Lilly Enters Licensing Agreement for Long-Acting Therapies in CVRM; Hims & Hers Reduces Workforce; AstraZeneca Initiates Ph3 Oral PCSK9i Program

Three cardiometabolic-related news items have been observed: Lilly entered into a licensing agreement with Camurus for long-acting drug delivery technology (view press release); Hims & Hers plans to cut 4% of its workforce (view article); and AstraZeneca initiated its Ph3 AZURE program for AZD0780 (oral PCSK9i) in patients with HeFH (AZURE-HeFH; view CT.gov record), elevated LDL (AZURE-LDL; view CT.gov record), and a CVOT (AZURE-Outcomes; view CT.gov record). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register

Already a member? Log in here

Regeneron Enters In-Licensing Agreement for Dual Agonist in Obesity and Announces Interim Ph2 Obesity Data; Nxera Achieves Milestone in Lilly Collaboration; TIXiMed Completes Ph1 Study for TIX100; Arrowhead Doses First Patients in Ph1/2a Obesity Study

A series of cardiometabolic-related news items has been observed from Regeneron Pharmaceuticals/Hansoh Pharma, Nxera Pharma, TIXiMed, and Arrowhead Pharmaceuticals. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register

Already a member? Log in here

Obesity Spotlight: If Pfizer Can’t Beat ‘Em, Should It Join Them?

In the fifth installment of FENIX’s Obesity Spotlight Series, FENIX has conducted a deep dive analysis of Pfizer’s current position in the obesity market. The analysis includes insights into Pfizer’s recent discontinuation of danuglipron (oral GLP-1RA; previous FENIX insight) and potential next steps for the company, including how Pfizer’s history with CVRM alliances may influence its obesity strategy.

This content is for Read Less members only.
Register

Already a member? Log in here

Novo Pushes Back Against Pharma Tariffs; Veru Ph2 Enobosarm Obesity Results; BioAge Completes IND-Enabling Studies for Obesity Asset

Three cardiometabolic-related news items have been observed: Novo Nordisk warns US government against pharma tariffs and encourages tariffs on compounded semaglutide (view article); Veru announced Ph2b topline safety results for its enobosarm + semaglutide study (view press release); and BioAge Labs announced preclinical findings for BGE-102 in obesity (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register

Already a member? Log in here

Evernorth Caps Wegovy and Zepbound Costs; Saxenda Pediatric CHMP Opinion

Two cardiometabolic-related news items have been observed: Evernorth Health Services announced a new pharmacy benefit capping the monthly OOP cost of Wegovy and Zepbound (view press release); and CHMP adopted a positive opinion for the Saxenda pediatric indication (view CHMP statement). Below, FENIX provides highlights and insights for the respective news items. 

This content is for Read Less members only.
Register

Already a member? Log in here

Novo Introduces New Wegovy Savings; Lilly’s Letter to Patients about Access; Sequel to Integrate with Abbott’s Glucose-ketone Sensor; Sernova Appoints Cell Pouch Advisory Board

A series of cardiometabolic-related news items has been observed from Novo Nordisk, Lilly, Sequel Med Tech/Abbott, and Sernova Biotherapeutics. FENIX will cover Cigna’s announcement regarding AOM coverage (view here) in today’s upcoming blast. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register

Already a member? Log in here

Noom Offers Lower-Dose Wegovy; Tandem’s Mobi Receives CE Mark; Ascletis Ph1 Obesity Study

Three cardiometabolic-related news items have been observed: Noom is offering lower doses of compounded Wegovy (view article); Tandem Diabetes Care’s Mobi insulin pump received CE Mark (view 8-K filing); and Ascletis Pharma announced dosing the first patient in its Ph1 ASC47 (THR-β) obesity study (view press release; view CT.gov record). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register

Already a member? Log in here

Skye Partners for Obesity Development; May CHMP Agenda; Altimmune Initiates Ph2 Study in AUD; Zealand Appoints New CDO; Cytokinetics Presents Additional Aficamten Analyses; Ionis Ph3 Olezarsen Topline Data

A series of cardiometabolic-related news items has been observed from Skye Bioscience, EMA, Altimmune, Zealand Pharma, Cytokinetics, and Ionis Pharmaceuticals. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register

Already a member? Log in here

Novo’s CEO Steps Down; Abbott Invests in Senseonics; Cellarity Hires Ex-Scholar Rock CFO

Three cardiometabolic-related news items have been observed: Novo Nordisk announced its current CEO, Lars Fruergaard Jørgensen, will step down amid an ongoing search for a successor (view press release); Abbott has invested in Senseonics (view press release); and Flagship’s company, Cellarity, appoints new CEO (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register

Already a member? Log in here